Policy & Regulation
European Commission approves Merck's ENFLONSIA for infant RSV prevention in Europe
17 April 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Friday that the European Commission has approved ENFLONSIA (clesrovimab) f...
Bold Therapeutics reports protection against chemotherapy-induced peripheral neuropathy with BOLD-100 anticancer agent
17 April 2026 - Canadian clinical-stage biopharmaceutical company Bold Therapeutics Inc on Thursday released new data highlighting the ability of its lead asset, BOLD-100, to demonstrate protective ef...
Adimab partner GSK receives additional marketing approvals for depemokimab
16 April 2026 - Adimab LLC, a provider of therapeutic antibody discovery and engineering technologies, said on Wednesday that it congratulates biopharmaceutical company GSK plc (LON:GSK) (NYSE:GSK) fo...
Seragon reports SRN-901 longevity drug data
16 April 2026 - Research-based biopharmaceutical company Seragon Biosciences Inc announced on Wednesday the publication of comprehensive preclinical study results in the peer-reviewed journal Drug Des...
Lunai Bioworks and Geneial enter into LOI to build rare disease patient cohorts for drug development partnerships
15 April 2026 - AI-driven drug discovery company Lunai Bioworks Inc (NASDAQ: LNAI) reported on Wednesday that it has entered into a non-binding Letter of Intent through its BioSymetrics subsidiary wit...
Circio partners with Acuitas to evaluate in vivo CAR-T cell therapy technology
15 April 2026 - Biotechnology company Circio Holding ASA (OSE:CRNA) announced on Wednesday that it has entered into an evaluation agreement with Canadian biotechnology company Acuitas Therapeutics to ...